Last reviewed · How we verify
NK105
NK105 is a nanosomal formulation of paclitaxel, a microtubule inhibitor.
NK105 is a nanosomal formulation of paclitaxel, a microtubule inhibitor. Used for Breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | NK105 |
|---|---|
| Sponsor | Nippon Kayaku Co., Ltd. |
| Drug class | Microtubule inhibitor |
| Target | Beta-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel works by binding to tubulin and stabilizing microtubules, thereby inhibiting cell division and inducing apoptosis in rapidly dividing cancer cells. The nanosomal formulation of NK105 is designed to improve the solubility and bioavailability of paclitaxel, allowing for more effective delivery to cancer cells.
Approved indications
- Breast cancer
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NK105 CI brief — competitive landscape report
- NK105 updates RSS · CI watch RSS
- Nippon Kayaku Co., Ltd. portfolio CI